Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1717662

registered interest
date	13/05/2024
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Immigration: Detainees
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, with reference to the Introduction to the Government Response to the Report of the European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment (CPT) on its visit to the United Kingdom from 27 March to 6 April 2023 (CPT/Inf (2024) 09), whether he has had recent discussion with Cabinet colleagues on the implications for their policies of the (a) conditions of detention and (b) treatment of persons held under immigration powers in the UK.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25992
answer	answer is ministerial correction date of answer 16/05/2024 answer text <p>Detention plays a key role in maintaining effective immigration control and securing the UK’s borders, particularly in connection with the removal of people who have no right to remain in the UK but who refuse to leave voluntarily.</p><p> </p><p>The Home Office takes the welfare and safety of people in its care very seriously and we are committed to ensuring the proper protection and treatment of people in detention.</p> answering member constituency Mid Dorset and North Poole answering member printed Michael Tomlinson question first answered 16/05/2024 13:35:15 answering member 4497 label Biography information for Michael Tomlinson
tabling member	4783 label Biography information for Kate Osborne

1716806

registered interest
date	09/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the availability of enzyme replacement therapy.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25591
answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 25370 25371 question first answered 15/05/2024 08:18:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4783 label Biography information for Kate Osborne

1716571

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that people who require enzyme replacement therapy receive that medication in a timely manner.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25370
answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 25371 25591 question first answered 15/05/2024 08:18:00 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4783 label Biography information for Kate Osborne

1716572

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with pharmaceutical companies on ensuring adequate supplies of (a) enzyme replacement therapy and (b) other related medications.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25371
answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 25370 25591 question first answered 15/05/2024 08:18:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4783 label Biography information for Kate Osborne

1716222

registered interest
date	07/05/2024
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Immigration: Detainees
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, with reference to the Government Response to the recommendation in paragraph 47 of the Report of the European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment (CPT) on its visit to the United Kingdom from 27 March to 6 April 2023 (CPT/Inf (2024) 09) that a healthcare professional be present during all Assessment, Care in Detention and Teamwork (ACDT) interviews in Immigration Removal Centres (IRCs), if he will take steps to address resourcing constraints of healthcare staff in order to meet the needs of mentally vulnerable people in detention.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25081
answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>Healthcare services in immigration detention facilities in England are commissioned by NHS England. We take our responsibility towards detained individuals seriously and work closely with NHS England to ensure the health and safety of people we detain is safeguarded.</p><p> </p><p>Healthcare staff attend Assessment, Care in Detention and Teamwork (ACDT) reviews where possible, and particularly if there are health concerns with the individual in question or a specific request for healthcare attendance has been made. <a href="https://www.gov.uk/government/publications/recording-attempted-self-harm-in-detention-centres" target="_blank">DSO 01/2022 Assessment care in detention and teamwork</a> provides guidance on the care and management of individuals under the ACDT process.</p> answering member constituency Mid Dorset and North Poole answering member printed Michael Tomlinson question first answered 14/05/2024 14:40:12 answering member 4497 label Biography information for Michael Tomlinson
tabling member	4783 label Biography information for Kate Osborne

1716223

registered interest
date	07/05/2024
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Immigration: Detainees
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, how many Rule 35(1) reports made by GPs working in Immigration Removal Centres setting out their concerns that continued detention of a person was likely to be injurious to their health were received by his Department from 1 January 2022 to 31 December 2023; how many such persons were released from detention as a result of such a report; and in how many cases was detention continued because his Department believed that the vulnerabilities identified by the medical practitioner were outweighed by immigration control factors.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25082
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>We regularly publish data on Rule 35(1) report from GPs in Immigration Removal Centres (IRCs).</p><p>For the information from 1 January 2022 to 31 December 2023. Information is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/immigration-enforcement-data-q4-2023" target="_blank">https://www.gov.uk/government/publications/immigration-enforcement-data-q4-2023</a>.</p><p>DT_03: Reports made by a medical practitioner to the Home Office under Rule 35 on individuals in immigration detention by level (1, 2 and 3).</p><p>To maintain the highest standards of accuracy, the Home Office refers to published data, as this has been subject to rigorous quality assurance under National Statistics protocols prior to publication.</p><p>We do not routinely publish information about whether continued detention could be harmful to a person’s health along with details on number of people released or where detention was continued for immigration control reasons.</p> answering member constituency Mid Dorset and North Poole answering member printed Michael Tomlinson question first answered 13/05/2024 10:50:30 answering member 4497 label Biography information for Michael Tomlinson
tabling member	4783 label Biography information for Kate Osborne

1714942

registered interest
date	30/04/2024
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Manuel Guerrero
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Deputy Foreign Secretary, whether he has made representations to the Qatari government on allegations of (a) mistreatment and (b) torture made by Manuel Avina Guerrero.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	24327
answer	answer is ministerial correction date of answer 09/05/2024 answer text <p>Supporting the welfare of British nationals detained overseas is a priority for the Foreign, Commonwealth and Development Office and we take all allegations of torture and mistreatment extremely seriously. When such concerns are raised, with the individual's consent, we will raise these with the relevant authorities. We are unable to provide comment on individual cases in line with relevant UK data protection legislation, which can be found at [https://www.gov.uk/government/organisations/foreign-commonwealth-development-office/about/personal-information-charter].</p> answering member constituency Macclesfield answering member printed David Rutley question first answered 09/05/2024 15:12:24 answering member 4033 label Biography information for David Rutley previous answer version 32803 answering member constituency Macclesfield answering member printed David Rutley answering member 4033 label Biography information for David Rutley
tabling member	4783 label Biography information for Kate Osborne